Oxford Science Enterprises

🏆 When it comes to spinouts, Oxford continues to lead the way – generating 225 spinout companies as of January 2025, up 7.1% from last year. The Royal Academy of Engineering Enterprise Hub has published its latest ‘Spotlight on Spinouts’ report in partnership with Beauhurst, highlighting the world-class talent and start-up activity spinning out of the UK. We’re thrilled that Oxford Science Enterprises was acknowledged as a key driver of this growth! Click below to read the full report – and look out for a mention of our portfolio company Amber Therapeutics. 🔗https://lnkd.in/e7q7N6zB #Spinouts

📢 #PortfolioNews: First Light Fusion has been awarded a £250,000 contract by the UK Atomic Energy Authority! ⚡   Fusion has the potential to provide the UK with secure energy for generations to come – but successful delivery means overcoming complex scientific and engineering challenges.    The contract will see First Light Fusion develop a remote measurement system for inertial fusion compression – a fusion energy process in the power plant environment.    Learn more below. https://lnkd.in/egnB8v5b   #OxfordScienceEnterprises #FusionEnergy

📢 #PortfolioNews: Endlyz Therapeutics has officially emerged from stealth and is initiating a Series A Raise! Unveiling a new portfolio of programmes targeting Parkinson’s disease, Endlyz’s pipeline represents first-in-class potential in restoring lysosomal function (the digestive system of a cell) to slow or halt the progression of Parkinson’s. And that’s not all – Endlyz has also announced $2.2 million in funding from the Michael J. Fox Foundation for Parkinson’s Research and a collaboration with Prof. Peter Vangheluwe, who joins as a scientific co-founder of the company. Please also join us in congratulating Joanna Wolak on her new role as CEO! Joanna co-founded Endlyz Therapeutics in 2021, and will lead the team through this next stage of growth. ➡️ https://lnkd.in/e6raS6S9 #OxfordScienceEnterprises #ParkinsonsDisease

🔦 What does a week in the OSE ecosystem look like? 🔬 ONI, a leader in super-resolution microscopy, is launching a new application kit which helps scientists to gain immediate insights with less human error. Read about it here: https://lnkd.in/eaAziEzG 📕 The University of Oxford research group led by Oxford Quantum Circuits (OQC) founder and CSO Dr Peter Leek announced research demonstrating the speed-up of 2Q gates – the fidelity of which is a key metric for building hardware towards useful quantum computers. Discover the research: https://lnkd.in/e7XJFSf6 🌿 Wild Bioscience has been recognised as a leading climate tech start-up by joining the cohort of Tech Nation's Climate Programme 2025. The four month accelerator will be key in driving Wild Bioscience’s use of genomics to unlock crop potential. 💬 Heather Roxborough, HealthTech Partner at OSE, will be speaking at the Tech London Advocates & Global Tech Advocates HealthTech Investor Showcase on Wednesday 02 April at HERE EAST. Come along to hear from leaders in the #HealthTech and #LifeSciences sectors while exploring how we can continue driving growth in this sector. Tickets are free: https://lnkd.in/evBfYbts #OxfordLifeSciences

💊 Sitryx reached a huge milestone last week, announcing the initiation of a first-in-human clinical trial for the treatment of atopic dermatitis – a chronic skin disease affecting over 200 million people worldwide. Sitryx is evaluating their treatment, named SYX-5219, as a potential disease-modifying therapy. As it stands, preclinical data has shown it reduces inflammation and enhances skin barrier repair. More than five million people in the US and Europe are living with a moderate to severe form of the disease, with symptoms that massively impact quality of life. It’s fantastic to see Sitryx’s progress in advancing a treatment to solve this problem. Read more about the trial here ➡️ https://lnkd.in/ecJatRFx #FirstInHuman #ClinicalTrial

🗞️ Did you spot our portfolio companies in the press this week?    🧬 The Department of Health and Social Care is prioritising sickness prevention policies once again, and Genomics’ genetic analytics technology is at the forefront of the revolution. The Times spoke to Genomics’ CEO and co-founder Sir Peter Donnelly to find out more: https://lnkd.in/eac229ww    💻 On Monday, science minister Lord Patrick Vallance visited Oxford Ionics to pick up ‘Quartet’ – one of the 12 quantum computers commissioned for use in the £140 million National Quantum Computing Centre – and to mark the opening of their brand new 30,000 sq foot HQ in Oxford. Read about it here: https://lnkd.in/eVMUYXx6    🎧 Wadham College Alumni’s ‘50 years of Women at Wadham College’ panel discussion is live across popular podcast platforms, featuring an inspiring discussion with stories from Monika Gullerova, Sophie Costello, Katerina Spranger, PhD 🇺🇦 and Diana Mandewo, moderated by OSE’s Life Sciences Partner, Claire Brown. Listen here: https://lnkd.in/edTnRbeX    #OxfordScienceEnterprises

📢 #PortfolioNews: Seloxium has raised £6M in seed funding to accelerate the commercialisation of its metal purification technology! Every year, vast quantities of valuable materials are lost through industrial processes, with $10BN worth of metals discarded from electronic waste alone. Seloxium's proprietary Selectal™ technology provides a fast and effective solution to extract valuable metals—such as rare earth elements and gold—from difficult-to-treat industrial and mining waste. This investment will enable the company to scale its technology and deployment, strengthening global supply chains and promoting sustainability practices worldwide. Learn more here: https://lnkd.in/evySvBQG

🤝 We’re pleased to welcome Mark Chadwick as our new Scientist-in-Residence (SIR) in the #DeepTech team. Mark holds an MChem and DPhil in Chemistry from the University of Oxford, and joins OSE after a distinguished academic career, most recently as a Research Fellow at Imperial College London. With a strong track record in cutting-edge chemical research, Mark will play a pivotal role in shaping our Deep Tech strategy, helping us identify and support the most promising research at the earliest stages. Learn more about Mark’s impressive career here: https://lnkd.in/eiXS9S_e

Spinouts are a high-value asset class offering immense economic potential for the UK. What role can pension funds play in unlocking this value? 🔓 We were pleased to attend the PLSA Investment Conference last week alongside Northern Gritstone and Cambridge Innovation Capital to explore this theme and more. Our CEO Edward Bussey joined a panel alongside Andrew Williamson, Managing Partner at Cambridge Innovation Capital; Duncan Johnson, CEO of Northern Gritstone and Julia Diez, Portfolio Manager at Railpen for a discussion on ‘Investing in the UK’s High Growth Science and Tech Ecosystem’. Many thanks to PLSA for inviting us to the panel, and to Head of DC, Master Trusts and Lifetime Savings Alyshia Harrington-Clark for facilitating a great conversation. Here is one of Ed’s key takeaways: “We have one of the most exciting asset classes to invest in in the UK on our doorstep right now. The rest of the world sees it and we really want to get the UK pension industry behind it.” Tune into the ‘Investment Uncut: PLSA 2025’ podcast for more insights from the conference. 🎧 https://lnkd.in/eK2KRUTc Pensions and Lifetime Savings Association | #PLSAInvest

Once an idea from Oxford University, now a spinout on the global stage. We’re pleased to share two incredible milestones from our portfolio companies this week: 1️⃣ Caristo Diagnostics has officially entered the US market after the FDA granted clearance for its CaRi-Plaque technology. The company uses AI-assisted image analysis to aid the diagnosis of coronary inflammation, which the Centers for Disease Control and Prevention says causes hundreds of thousands of heart attacks and strokes in the US every year. 2️⃣ Oxford Ionics has been selected by the UK’s Department for Science, Innovation and Technology (DSIT) and Innovate UK for the ‘Quantum Missions’ pilot, designed to invest in projects that overcome technological barriers to large-scale commercialisation of quantum. As a world record holder in all three of quantum computing’s super metrics, we couldn’t think of someone better-suited for the programme! 📈 Learn more about Caristo Diagnostics and Oxford Ionics in the comments. #OxfordScienceEnterprises